News
3h
AllAfrica on MSNGlobal Fund Secures Access to Breakthrough HIV Prevention Drug Lenacapavir for Low - and Middle-Income CountriesA pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they liveThe Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) ...
The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...
Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
In early 2025, the US decision to halt foreign aid for HIV/AIDS programs triggered global concerns about a potential ...
Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...
Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...
Independent Online (IOL) on MSN16h
Poorer countries granted access to HIV prevention drugGlobal Fund aims for the first shipment to reach at least one African country by year-end. Read more at straitstimes.com.
The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...
Nearly 40 million individuals globally are currently living with HIV, a virus that has resulted in the loss of over 42 ...
Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results